[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Britain’s GSK to buy Affinivax in $3.3 billion deal

05/31/2022

Less than a minute

2022.05.31 09:26

Britain's GSK to buy Affinivax in $3.3 billion deal
FILE PHOTO: Signage for GlaxoSmithKline is seen on it’s offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo

(Reuters) – British drugmaker GSK said on Tuesday it would pay up to $3.3 billion to acquire privately held biopharmaceutical firm Affinivax, as it seeks to bolster its vaccine pipeline.

Source

05/31/2022

Less than a minute